TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems of the wider motor system, including the brain, nerves and muscles. The authors say muscle mass alone does not explain much of the decline in strength, but their proposed assessment changes have not yet been shown to improve outcomes or reduce costs.
Researchers are calling for sarcopenia—the loss of strength and physical function associated with aging—to be understood as a problem of the whole motor system, not just shrinking muscles. In a 2026 paper in The Lancet Healthy Longevity, the authors argue that changes in the brain, nerves, balance and movement control may help explain why older adults lose mobility, though their proposed clinical approach still needs testing.
The authors say the definition of sarcopenia has already shifted toward measures such as grip strength, walking speed and chair stands, because these indicators predict falls, disability and death better than muscle mass alone. But they argue that the explanation used in research and clinical practice has not kept pace: weakness is still often treated as a direct consequence of muscle wasting.
According to the paper, muscle loss accounts for only a modest share of the decline in strength among older adults. People with similar muscle mass can have different levels of strength and mobility, while exercise can improve function even when measurable muscle mass does not change. The researchers say this points to other influences on movement and physical performance.
The proposed wider frame includes the brain and spinal cord, nerves, connections to muscle, balance and position sense. The authors describe age-related changes that may slow movement planning and make nerve signals less reliable or weaker. They also highlight power—the ability to produce force quickly—as important for everyday actions such as standing from a chair, saying it can decline earlier and faster than muscle mass.
A Wider Lens on Mobility Loss
The argument could affect how clinicians and researchers investigate weakness, falls and loss of independence. If poor mobility reflects changes across the motor system, treatments aimed mainly at increasing muscle mass may not address all the reasons a person is struggling to walk, rise or stay balanced. The authors say a broader model could support more individualized assessment and multicomponent care.
The issue has substantial public-health relevance in Australia, the setting highlighted by the report. It says sarcopenia affects up to 29% of community-dwelling older adults, with higher rates in hospitals and residential elder care and among people with multiple conditions or frailty. The report also cites 253,800 fall-related hospitalizations in Australia in 2024–25, and 6,722 deaths following falls in the preceding year. These figures describe falls, not cases caused solely by sarcopenia.
For patients, the proposed change is not a new diagnosis or established treatment. It is a call to look beyond muscle size when assessing declining function, while gathering evidence about which additional checks are practical and useful.
Products Worth Considering
Bowflex PR1000 Home Gym
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Function
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm to guide primary-care screening, assessment and management of poor muscle health. The Medical Xpress report described that as a step toward bringing the issue into routine care. The new paper adds a challenge to the underlying model: what clinicians measure has changed more than the explanation for why strength and mobility decline.
The paper, by Lucas B. R. Orssatto and colleagues, sets out a five-point agenda for international working groups responsible for diagnostic criteria. For primary care, the authors suggest retaining strength and gait-speed measures while also paying attention to how quickly a patient rises from a chair, unsteadiness during sustained effort, hand dexterity and changes in walking when a person talks at the same time. They advise closer examination when weakness is asymmetric, rapid or out of proportion to muscle loss.
The authors also say medication review should accompany strength training, noting that sedative and anticholinergic medicines can blunt motor drive. This is a proposed clinical consideration, not evidence that changing medication will prevent or reverse mobility loss for every patient.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and co-authors, in The Lancet Healthy Longevity
Tests and Benefits Still Unproven
The paper presents a reframing and research agenda, not proof that motor-system assessments outperform existing methods. The authors say no study has yet shown that the suggested measures improve patient outcomes or offer better value for money. It is also unclear which additional checks can be used reliably in ordinary primary care, where access to neuromuscular expertise varies.
The report does not establish how much of an individual patient’s weakness comes from muscle loss, nerve or brain changes, medication effects, or other health conditions. Nor does it show that a particular intervention targeting the wider motor system will prevent falls or preserve independence. Those questions require validation studies and clinical trials that measure nerve and muscle outcomes alongside everyday function.
Validation Before Practice Changes
The authors are asking international groups that develop sarcopenia diagnostic criteria to consider their five-point agenda. They also call for investment in practical tests, guidelines that support a staged assessment and clinical trials that examine both nerve and muscle contributions to movement.
For now, the proposed checks should be understood as suggestions from the paper rather than a replacement for current screening or individualized clinical judgment. The next key development will be evidence showing whether these measures can identify relevant causes of weakness more accurately—and whether using them leads to better mobility, fewer falls or other meaningful benefits.
Key Questions
What does the paper say sarcopenia involves?
The authors argue that sarcopenia involves more than muscle loss. They propose that age-related changes in the brain, spinal cord, nerves, balance and muscle connections may also contribute to weakness and mobility problems.
Is this a new diagnostic standard?
No. The paper offers a proposed reframing and research agenda. Its authors say the suggested assessment measures have not been shown to outperform existing screens on patient outcomes or cost.
What signs do the researchers suggest clinicians notice?
Along with strength and walking speed, they suggest paying attention to the speed of rising from a chair, unsteadiness during sustained effort, hand dexterity and walking while talking. These are proposals for assessment, not a validated standalone test.
Why does the motor-system explanation matter?
If weakness can arise from problems beyond muscle mass, focusing only on building muscle may miss other contributors to reduced movement. The authors say a broader approach could guide more targeted research and care, but that benefit remains to be tested.
Source: medicalxpress.com
